Descripción de la empresa
Cellyan Biotechnology Co., Ltd operates as an investment holding company focused on the over-the-counter pharmaceutical sector, providing cross-border procurement, distribution, and e-commerce supply chain services within Hong Kong and Mainland China. The enterprise functions within the healthcare sector, specifically classified under the industry of pharmaceutical retailers, which implies a business model centered on the retail sale of non-prescription medications to consumers. This entity maintains a relatively modest operational scale, employing a workforce of 27 individuals while reporting a total market capitalization of $12.22M and annual revenue of $16.36M. The valuation metrics indicate that the company is a small-cap entity with limited market penetration compared to larger pharmaceutical distributors, as evidenced by its market cap being significantly below typical industry leaders and its revenue reflecting a niche operational footprint in the regional OTC market.
Salud financiera
The company reported total revenue of $16.36M over the trailing twelve months, yet it recorded a net income of $-701,880 and an EBITDA of $-534,478, revealing a significant cost structure where operating expenses and losses heavily outweigh gross profits. Despite the negative net income, the firm generated positive free cash flow of $2.44M, which suggests a degree of financial flexibility allowing for operational continuity or strategic reinvestment despite accounting losses. The company's profitability margins are under pressure, evidenced by a gross margin of 8.8%, an operating margin of 3.0%, and a negative profit margin of -4.3%, indicating that the business struggles to retain earnings after covering both variable and fixed costs. On the balance sheet, the firm holds $2.48M in cash against $2.27M in debt, resulting in a debt-to-equity ratio of 44.19% that suggests a moderately leveraged but not distressed position given the liquidity available. Liquidity is supported by a current ratio of 2.93, which indicates a robust ability to meet short-term obligations with current assets. However, the return metrics paint a picture of inefficiency, with a return on equity of -13.4% and a return on assets of -3.9%, signaling that management is currently unable to generate positive returns on the capital invested or deployed by the company.
Evaluación de valoración
Valuation multiples for Cellyan Biotechnology Co., Ltd are difficult to interpret using traditional earnings metrics due to the lack of a trailing P/E ratio and a forward P/E ratio, both listed as N/A, which implies that earnings-based valuation models are not applicable given the company's loss-making status. Instead, the market values the company based on its tangible assets, reflected in a price-to-book ratio of 1.11, indicating that the stock trades at a slight premium over its book value per share. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 0.75 and an EV/EBITDA of -10.31, suggesting that the market is pricing the company primarily on its revenue generation potential rather than profitability or cash flow efficiency. The stock's price volatility is contextualized by a 52-week high of $2.76 and a 52-week low of $0.37, meaning the current price sits at a position that requires specific calculation relative to this range, highlighting the significant swing in share price over the last year. The beta value is listed as N/A, which indicates that the stock's price volatility relative to the broader market cannot be quantified with standard historical data, potentially due to low liquidity or limited trading volume in the OTC market.
Growth & Income
The company is currently experiencing contraction in both key performance indicators, with revenue growth year-over-year at -35.7% and earnings growth year-over-year at -83.1%. This divergence indicates that earnings are declining at a much faster rate than revenue, suggesting that cost reductions or operational efficiencies have not been able to offset the sharp decline in sales volume or market demand. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that no dividends are distributed to shareholders and any retained earnings are effectively reinvested into the business or used to service debt rather than being distributed. The overall growth and income profile of Cellyan Biotechnology Co., Ltd is characterized by significant negative growth trends and a complete absence of dividend income, presenting a scenario where the company relies entirely on capital appreciation or operational turnaround to generate value for its equity holders.